Mechanism-first
We begin with the biology of cell-cycle regulation and identify the patients most likely to respond.
Precision Oncology
More choice.
More possibility.
Zentia is unlocking a new targeted approach to cancer — a biomarker-driven, oral therapy designed to give physicians and patients more options where few non-chemotherapy treatments exist today.
- Global registration-intent trials
- 300+ patients dosed
- NASDAQ: ZNTA
Recognized for rigor at every stage
- FDA-aligned endpoints
- EMA review
- Good Clinical Practice
- ISO 27001
- Global trial network
0
Years of targeted kinase research
0
Late-stage clinical programs
0
Clinical trial sites worldwide
0
Peer-reviewed publications
Phase 3 · ASPENOVA
First patient dosed
Cyclin E1-positive platinum-resistant ovarian cancer
Innovating for patients
A differentiated, targeted approach where patients need it most
Zentia is developing an oral, first-in-class therapy that targets a central regulator of cell-cycle progression — breaking down the safeguards that cancer cells rely on to survive and grow.
Built on more than a decade of WEE1 biology, our lead candidate is designed to provide physicians and patients a choice for a targeted, non-chemotherapy option where few alternatives exist today.
- Oral, at-home administration — no infusion visits
- Biomarker-defined patient selection
- Registration-intent global development program
Our approach
A new kind of biomarker-directed medicine
We translate deep mechanistic science into therapies matched to the biology of each patient's disease — not just to a tumor type.
Our mission is clear — to unburden patients through a more convenient, targeted approach to cancer care.— Zentia Leadership Team
Companion diagnostics
Biomarker-driven enrollment pairs each patient with the therapy most relevant to their tumor's biology.
Patient-centered design
An oral, once-daily formulation designed to fit into daily life — not a hospital schedule.
How we work
From discovery to patient impact
-
01
Discovery
Deep mechanistic biology of cell-cycle control pinpoints novel, druggable targets.
-
02
Preclinical
Compound selection, biomarker validation and registration-ready study design.
-
03
Clinical development
Global, biomarker-driven trials advancing from first-in-human to registration.
-
04
Patient impact
An oral, convenient therapy designed to unburden patients and their families.
Pipeline
Clinical programs built on WEE1 biology
A focused, late-stage pipeline led by azenosertib-class therapy across biomarker-defined patient populations.
- DesignRegistration-intent, global
- Patient markerCyclin E1 positive
- DosingOral, once daily
- StatusEnrolling
- DesignRegistration-intent, global
- Patient markerBiomarker-defined
- DosingOral, once daily
- StatusAdvancing
- ScopeMultiple indications
- CombinationsRational, biomarker-led
- DosingOral, once daily
- StatusExploring
Get to know us
Learn more about Zentia
Pipeline
Our lead therapy anchors a focused, late-stage program across biomarker-defined patient populations.
View our progressInvestor presentation
We have built a disciplined, late-stage pipeline with a clear path to registration and commercial value.
Download presentationOur leadership
Led by experience — a disciplined team with a proven track record in oncology drug development.
Meet the teamContact us
Whether you're a patient, physician or investor — our team is here to help.
Get in touchVoices
What our community is saying
An oral therapy that patients can take at home is a meaningful shift. The biomarker-driven design means we can finally match the right patient to the right treatment.
The team's depth of WEE1 biology is unmatched. It's rare to see a program so thoughtfully designed around the underlying science of the disease.
As a patient, the idea of a more convenient option — without infusion visits — gives me real hope. Zentia treats us like people, not just diagnoses.
Patient resources
Thinking about a clinical trial?
Find trial sites near you and learn what to expect at every step.
For patients & physicians
Frequently asked questions
Answers about our investigational therapy, clinical trials, and what participation involves. Always speak with your care team about what's right for you.
Our lead candidate is an oral, once-daily kinase inhibitor taken at home. It targets a key regulator of cell-cycle progression that cancer cells depend on to survive and divide.
Trials use a companion diagnostic to identify biomarker-positive patients whose tumors carry Cyclin E1 amplification — pairing each person with the therapy most relevant to their disease biology.
No. It is a targeted therapy designed to interrupt a specific mechanism in cancer cells. It is being developed as a non-chemotherapy option with a more convenient, oral administration.
Contact our patient information team or speak with your oncologist. We can help identify a participating site and connect you with the trial team to confirm eligibility.